Search Results - "Thomas, Dean N."

Ames test study designs for nitrosamine mutagenicity testing: qualitative and quantitative analysis of key assay parameters by Thomas, Dean N, Wills, John W, Tracey, Helen, Baldwin, Sandy J, Burman, Mark, Williams, Abbie N, Harte, Danielle S G, Buckley, Ruby A, Lynch, Anthony M

“…The robust control of genotoxic N-nitrosamine (NA) impurities is an important safety consideration for the pharmaceutical industry, especially considering…”
Get full text

The exploration of aza-quinolines as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors with low brain exposure by Cadilla, Rodolfo, Deaton, David N., Do, Young, Elkins, Patricia A., Ennulat, Daniela, Guss, Jeffrey H., Holt, Jason, Jeune, Michael R., King, Andrew G., Klapwijk, Jan C., Kramer, H. Fritz, Kramer, Nicholas J., Laffan, Susan B., Masuria, Paresh I., McDougal, Alan V., Mortenson, Paul N., Musetti, Caterina, Peckham, Gregory E., Pietrak, Beth L., Poole, Chuck, Price, Daniel J., Rendina, Alan R., Sati, Girish, Saxty, Gordon, Shearer, Barry G., Shewchuk, Lisa M., Sneddon, Helen F., Stewart, Eugene L., Stuart, J. Darren, Thomas, Dean N., Thomson, Stephen A., Ward, Paris, Wilson, Joseph W., Xu, Tiahshun, Youngman, Mark A.

“…[Display omitted] GlaxoSmithKline and Astex Pharmaceuticals recently disclosed the discovery of the potent H-PGDS inhibitor GSK2894631A 1a (IC50 = 9.9 nM) as…”
Get full text

Resolution of Historically Discordant Ames Test Negative / Rodent Carcinogenicity Positive N-nitrosamines using a Sensitive, OECD-aligned Design by Thomas, Dean N, Wills, John W, Burman, Mark, Williams, Abbie N, Harte, Danielle S G, Buckley, Ruby A, Urquhart, Mike W, Bretonnet, Anne-Sophie, Jeffries, Benjamin, White, Angela T, Harvey, James S, Howe, Jonathan R, Lynch, Anthony M

“…The in vitro Bacterial Reverse Mutation (Ames) Test is crucial for evaluating the mutagenicity of pharmaceutical impurities. For N-nitrosamines (NAs)…”
Get full text